Rodger J Elble, William G Ondo, Kelly E Lyons, Min Qin, Svetlana Garafola, Bonnie Hersh, TinaMarie Lieu, Dimitrios Arkilo, Rosalind Chuang, Kemi Bankole, Rajesh Pahwa
BACKGROUND: SAGE-324/BIIB124 is an investigational positive allosteric modulator of GABAA receptors. OBJECTIVE: KINETIC (NCT04305275), a double-blind, randomized, placebo-controlled, phase 2 study, evaluated SAGE-324/BIIB124 in individuals with essential tremor (ET). METHODS: Individuals aged 18 to 80 years were randomly assigned 1:1 to orally receive 60 mg of SAGE-324/BIIB124 or placebo once daily for 28 days. The primary endpoint was change from baseline in The Essential Tremor Rating Assessment Scale-Performance Subscale (TETRAS-PS) Item 4 (upper-limb tremor) at day 29 with SAGE-324/BIIB124 versus placebo...
February 15, 2024: Movement Disorders: Official Journal of the Movement Disorder Society